AI Verdict
AAPL has stronger fundamentals based on our AI analysis.
RPRX vs AAPL Fundamental Comparison
| Metric | RPRX | AAPL |
|---|---|---|
| Revenue | $2.4B | $143.8B |
| Net Income | $770.9M | $42.1B |
| Net Margin | 32.4% | 29.3% |
| ROE | 7.9% | 47.7% |
| ROA | 3.9% | 11.1% |
| Current Ratio | 2.40x | 0.97x |
| Debt/Equity | 0.92x | 1.00x |
| EPS | $1.78 | $2.84 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RPRX vs AAPL: Frequently Asked Questions
Is RPRX or AAPL a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), AAPL has stronger fundamentals. RPRX is rated HOLD (75% confidence) while AAPL is rated BUY (87% confidence). This is not investment advice.
How does RPRX compare to AAPL fundamentally?
Royalty Pharma plc has ROE of 7.9% vs Apple Inc.'s 47.7%. Net margins are 32.4% vs 29.3% respectively.
Which stock pays higher dividends, RPRX or AAPL?
RPRX has a dividend yield of N/A or no dividend while AAPL has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RPRX or AAPL for long term?
For long-term investing, consider that RPRX has HOLD rating with 75% confidence, while AAPL has BUY rating with 87% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RPRX vs AAPL?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RPRX vs AAPL, the AI consensus favors AAPL based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.